

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/C91EDEAC134EN.html>

Date: June 2018

Pages: 59

Price: US\$ 3,500.00 (Single User License)

ID: C91EDEAC134EN

Abstracts

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2018'; Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 9 molecules.

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1 and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine.

The report 'Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2018' outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III and Preclinical stages are 1, 3 and 5 respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders and Undisclosed which include indications Migraine, Dental Pain, Diabetic Neuropathy, Inflammatory Pain, Nerve Injury, Neuropathic Pain, Post-Operative Pain and Unspecified.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)

The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects

The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Overview

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development

Allergan Plc

Amgen Inc

Biohaven Pharmaceutical Holding Company Ltd

Fortress Biotech Inc

Heptares Therapeutics Ltd

Merck & Co Inc

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles

A-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atogepant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BHV-3500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGRP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erenumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-0022562 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8825 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rimegepant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ubrogepant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Products

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Product Development Milestones

Featured News & Press Releases

Jun 01, 2018: Novartis receives positive CHMP opinion for Aimovig (erenumab) for the prevention of migraine

May 18, 2018: Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention

Apr 27, 2018: Allergan Announces Second Positive Phase 3 Clinical Trial for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Apr 22, 2018: Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor

Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine

Apr 19, 2018: Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles

Apr 17, 2018: Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig (erenumab) For Migraine Patients With Multiple Treatment Failures

Mar 26, 2018: Biohaven Announces Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Mar 06, 2018: Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis ODT In The Acute Treatment Of Migraine

Mar 01, 2018: Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis Orally Dissolving Tablet

Feb 06, 2018: Allergan Announces Positive Top Line Phase 3 Results for Ubrogapant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Jan 22, 2018: Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments

Nov 29, 2017: Aimovig (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention

Nov 27, 2017: Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant

Nov 20, 2017: Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine

Nov 16, 2017: Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Allergan Plc, H1 2018

Pipeline by Amgen Inc, H1 2018

Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018

Pipeline by Fortress Biotech Inc, H1 2018

Pipeline by Heptares Therapeutics Ltd, H1 2018

Pipeline by Merck & Co Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Allergan Plc

Amgen Inc

Biohaven Pharmaceutical Holding Company Ltd

Fortress Biotech Inc

Heptares Therapeutics Ltd

Merck & Co Inc

I would like to order

Product name: Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/C91EDEAC134EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C91EDEAC134EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

